The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
iwHRMM 2025 | Investigating the efficacy of allogeneic and in vivo CAR T-cell therapies in myeloma
Karlo Perica, MD, PhD, Memorial Sloan Kettering Cancer Center, New York, NY, outlines early evidence demonstrating the potential efficacy of allogeneic and in vivo CAR T-cell therapies in multiple myeloma (MM). Dr Perica emphasizes that the field is still in its early days and looks forward to future data from clinical trials assessing these cellular therapy approaches. This interview took place at the 2nd International Workshop on High-Risk Multiple Myeloma (iwHRMM 2025), held in Charleston, SC.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
For allogeneic CAR T-cells, we’ve had several trials reported out. For example, Sham Mailankody from our center was the first author on a trial based off the technologies developed by Selective Cellecta, Celgene and Allogene, the product by Allogene, which did report efficacy. It has unfortunately been associated with toxicity due to the immune suppression strategy that they use to prevent rejection of the cells...
For allogeneic CAR T-cells, we’ve had several trials reported out. For example, Sham Mailankody from our center was the first author on a trial based off the technologies developed by Selective Cellecta, Celgene and Allogene, the product by Allogene, which did report efficacy. It has unfortunately been associated with toxicity due to the immune suppression strategy that they use to prevent rejection of the cells. Furthermore, while there is activity, I think the challenge of those trials has been to try to figure out how much activity is enough. We’re all looking for a home run. We’re all looking for a clear answer that allogeneic CAR T-cells are better than autologous CAR T-cells, and we definitely haven’t seen that. So there is still an open question of how we design trials that will tell us when an allogeneic product is sufficiently active or more active than an autologous counterpart, such that it’s worth developing further and eventually can become a standard therapy.
In the in vivo space, we’re very much in early days. We’re just starting to see the first clinical reports of patients treated, mostly in China, but also in the United States. Reports of three to four patients with encouraging activity. We’re already starting to see the first myeloma patients that have achieved stringent CRs with virally-based approaches, referring to the recent report from SL Biotech. However, it is very early days. So we are really excited over the next year or two to see further reports in myeloma, in lymphoma, and increasingly in autoimmunity of in vivo CAR T-cells.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
